Tirzepatide vs Semaglutide: Which GLP-1 Drug Produces Greater Weight Loss?

Understanding the Fundamental Difference: GLP-1 vs Dual Agonism

Before comparing clinical outcomes, it is essential to understand why these two drugs differ at the molecular level. Both semaglutide and tirzepatide belong to the broader class of incretin-based therapies, but they engage the body's hormonal signaling pathways in meaningfully different ways — and those differences appear to translate into measurably different clinical outcomes.

What Semaglutide Does: Single GLP-1 Receptor Agonism

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a naturally occurring incretin hormone secreted by L-cells in the small intestine in response to food. Under normal physiological conditions, GLP-1 is released after eating and triggers a cascade of beneficial metabolic effects:

• Stimulates glucose-dependent insulin secretion — the pancreas releases insulin only when blood glucose is elevated, reducing hypoglycemia risk
• Suppresses glucagon release — prevents the liver from inappropriately dumping glucose into the bloodstream
• Slows gastric emptying — food moves from the stomach to the intestine more slowly, blunting postprandial glucose spikes
• Acts on the brain's satiety centers — specifically the hypothalamus and brainstem, reducing hunger signals and increasing feelings of fullness

Semaglutide is a synthetic analog of human GLP-1, modified to resist enzymatic degradation (by DPP-4) and extend its half-life to approximately one week — enabling once-weekly dosing. Its binding affinity to GLP-1 receptors is very high, and it crosses the blood-brain barrier to a degree that is clinically meaningful for appetite suppression.

What Tirzepatide Does: Dual GIP/GLP-1 Receptor Agonism

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. GIP is the other major incretin hormone, secreted by K-cells in the duodenum. While GIP was historically considered a weaker incretin (and even potentially pro-obesity at high levels), its interaction with GLP-1 signaling in a pharmacological context appears to produce synergistic effects.

The key question researchers asked was: does adding GIP agonism on top of GLP-1 agonism produce meaningfully better outcomes? The SURMOUNT and SURPASS trial programs suggest the answer is yes — at least for weight loss.

Tirzepatide is a single synthetic peptide molecule engineered to activate both receptors. It is not a co-formulation of two drugs — it is one molecule with dual receptor activity, given as a once-weekly subcutaneous injection in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

The STEP Trials: Semaglutide's Clinical Evidence Base

Novo Nordisk conducted the STEP (Semaglutide Treatment Effect in People with Obesity) trial program to support FDA approval of semaglutide 2.4 mg (Wegovy) for chronic weight management. The program included four pivotal trials published between 2021 and 2022.

STEP 1 — The Landmark Trial

STEP 1 (published in The New England Journal of Medicine, 2021) enrolled 1,961 adults with a BMI ≥ 30 kg/m² (or ≥ 27 with at least one weight-related comorbidity) who did not have diabetes. Participants received semaglutide 2.4 mg subcutaneously once weekly or placebo, alongside lifestyle intervention, over 68 weeks.

Key results at 68 weeks:

• Mean weight loss with semaglutide: −14.9% of body weight (approximately 15.3 kg)
• Mean weight loss with placebo: −2.4%
• 86% of semaglutide participants lost at least 5% of body weight
• 69% lost at least 10%
• 50% lost at least 15%
• 32% lost at least 20%

STEP 2 — Patients With Type 2 Diabetes

STEP 2 specifically enrolled 1,210 adults with both obesity and type 2 diabetes — a population that generally shows attenuated response to weight loss interventions. Semaglutide 2.4 mg produced a mean weight reduction of −9.6% versus −3.4% with placebo at 68 weeks. The blunted response compared to STEP 1 is consistent across GLP-1 class effects and mirrors what was seen in tirzepatide's diabetic cohorts as well.

STEP 4 — What Happens When You Stop

Perhaps the most clinically important STEP trial was STEP 4, which studied what happens when patients discontinue semaglutide after 20 weeks of treatment. After stopping the drug, participants regained approximately two-thirds of the weight they had lost within 48 weeks, and most metabolic improvements reversed. This trial established clearly that these medications require long-term, if not indefinite, use for sustained benefit — a point of significant practical and economic importance.

The SURMOUNT Trials: Tirzepatide's Weight Loss Evidence

Eli Lilly's SURMOUNT trial program evaluated tirzepatide specifically for weight management in people without diabetes (the drug was already approved for type 2 diabetes under the SURPASS program as Mounjaro before SURMOUNT data supported FDA approval of Zepbound for obesity).

SURMOUNT-1 — The Defining Trial

SURMOUNT-1 (published in The New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity (BMI ≥ 30, or ≥ 27 with comorbidities) without type 2 diabetes. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks.

Results at 72 weeks by dose:

• Tirzepatide 5 mg: −15.0% body weight (approximately 15.4 kg)
• Tirzepatide 10 mg: −19.5% body weight (approximately 19.5 kg)
• Tirzepatide 15 mg: −20.9% body weight (approximately 20.9 kg)
• Placebo: −3.1%

Critically, the proportion of participants achieving ≥20% weight loss at the 15 mg dose was 63% — a threshold that has historically only been achievable with bariatric surgery. Even at 5 mg, 32% achieved ≥15% weight loss.

SURMOUNT-2 — Patients With Type 2 Diabetes

SURMOUNT-2 enrolled patients with obesity and type 2 diabetes. Results showed mean weight losses of −13.4% (10 mg) and −15.7% (15 mg) at 72 weeks. As with semaglutide, the presence of diabetes attenuates weight loss response, but tirzepatide still outperformed semaglutide's STEP 2 results in a comparable population.

Side Effect Comparison: Tolerability Across Both Drugs

Both tirzepatide and semaglutide share a broadly similar tolerability profile, which is expected given their overlapping mechanism (both are GLP-1 receptor agonists). Gastrointestinal side effects predominate, particularly during dose escalation phases.

Gastrointestinal Effects

The most common adverse effects for both drugs are:

• Nausea — the most frequently reported side effect, especially in the first 4–8 weeks
• Vomiting
• Diarrhea
• Constipation — particularly notable with semaglutide
• Abdominal pain / dyspepsia

In STEP 1, nausea was reported by approximately 44% of semaglutide participants versus 16% of placebo participants. Vomiting occurred in approximately 24% of the semaglutide group. Discontinuation due to GI adverse events was approximately 4.5%.

In SURMOUNT-1, nausea rates for tirzepatide ranged from approximately 25% to 33% depending on dose, with vomiting rates of 11–13%. Discontinuation due to GI adverse events was 4.3–5.0%. These rates appear modestly lower than semaglutide, though cross-trial comparisons carry caveats.

Some researchers have proposed that GIP agonism may actually reduce nausea signaling in the brainstem area postrema, potentially explaining tirzepatide's apparently better GI tolerability relative to its weight loss efficacy — though this remains mechanistically speculative.

Serious Adverse Events

Both drugs carry FDA black box warnings and precautions that patients must understand:

• Thyroid C-cell tumors: Both drugs caused thyroid C-cell tumors in rodents at clinical doses. This has not been observed in human clinical trials or post-market surveillance, but both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis: Acute pancreatitis has been reported. Patients with a history of pancreatitis should discuss risks with their physician. Both drugs should be discontinued if pancreatitis is suspected.
• Gallbladder disease: Rapid weight loss of any cause increases gallstone risk, and GLP-1 medications may independently slow gallbladder emptying. Cholelithiasis and cholecystitis rates were modestly elevated in trial data for both drugs.
• Diabetic retinopathy: Rapid improvement in glycemic control (as seen particularly in patients with diabetes using these drugs) can transiently worsen pre-existing diabetic retinopathy. Ophthalmologic monitoring is recommended in this population.
• Heart rate increase: Both semaglutide and tirzepatide can modestly increase resting heart rate by 2–4 beats per minute. The clinical significance appears limited based on cardiovascular outcome trials, but patients with underlying arrhythmias should discuss this with their physician.

Muscle Mass Considerations

One area of legitimate concern is lean mass preservation during GLP-1-induced weight loss. Clinical analyses of STEP and SURMOUNT trials showed that approximately 25–40% of weight lost may come from lean mass (muscle), rather than exclusively fat mass. This ratio is broadly similar to other caloric restriction approaches, and resistance exercise training can substantially mitigate lean mass loss.

Patients on these medications are strongly encouraged to engage in resistance training and maintain adequate protein intake (generally 1.2–1.6 g of protein per kg of body weight per day) throughout treatment.

Brand Names Explained: Mounjaro, Zepbound, Ozempic, Wegovy

One of the most common sources of confusion for patients is the relationship between brand names and active ingredients. The key rule: brand names differ by FDA-approved indication, not by drug formulation.

Tirzepatide Brand Names

• Mounjaro (tirzepatide): FDA-approved May 2022 for adults with type 2 diabetes to improve glycemic control. Available in 2.5–15 mg once-weekly doses.
• Zepbound (tirzepatide): FDA-approved November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27 with comorbidities). Same molecule, same doses, different label and indication.

Semaglutide Brand Names

• Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg): FDA-approved December 2017 for type 2 diabetes and cardiovascular risk reduction. Also holds an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (based on the SUSTAIN-6 and SELECT trials).
• Wegovy (semaglutide 2.4 mg): FDA-approved June 2021 for chronic weight management. Higher dose formulation than Ozempic, specifically studied in the STEP program.
• Rybelsus (semaglutide 7 mg, 14 mg): An oral tablet formulation of semaglutide approved for type 2 diabetes. Not studied for weight management at these doses and generally produces less weight loss than injectable forms due to lower bioavailability.

Insurance Coverage, Cost, and Access

Cost and coverage remain the most significant real-world barriers to both medications for most patients. As of 2024:

• List prices for both Wegovy and Zepbound exceed $1,000/month without insurance coverage.
• Diabetes indications (Ozempic, Mounjaro) are more likely to receive insurance coverage than obesity indications (Wegovy, Zepbound), reflecting persistent gaps in insurance coverage for obesity as a medical condition.
• Both Novo Nordisk and Eli Lilly offer savings programs for commercially insured patients — check each company's patient assistance pages for current terms, as these change frequently.
• Compounded versions of semaglutide and tirzepatide have been widely available during drug shortage periods; the FDA has taken regulatory action to limit compounding as supply has normalized. Patients should be cautious about compounded versions from sources of uncertain quality.

Clinical Evidence at a Glance